Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL-Frail2: Zanubrutinib +/- Sonrotoclax in Older/Frail Treatment-Naïve CLL
NCT07899398Phase 2Not yet recruiting
- Sponsor
- German CLL Study Group
- Start
- Dec 2026
- Primary completion
- Jan 2029
01
Overview
Phase 2, randomised, open-label trial in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) comparing Arm A - Zanubrutinib with Arm B - Zanubrutinib/Sonrotoclax (2 arms). Primary endpoint: Progression-free survival up to 24 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
zanubrutinibsonrotoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07899398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07899398.